Partnering with Janssen Pharmaceuticals

The Johnson & Johnson Innovation, Janssen Business Development team pursues partner opportunities that will accelerate the creation of healthcare solutions that improve peoples’ lives around the world. We seek to create value in six defined therapeutic areas: Cardiovascular & Metabolism; Immunology; Infectious Diseases and Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Janssen Business Development is very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, including joint ventures, development collaborations, commercial partnerships with established pharmaceutical companies and mid- to large-size biotechnology companies.

With a strong vision, a culture of caring, and an intention to invest in the future, we are committed to take partnering for health and wellbeing to a new level.

At Johnson & Johnson, the decentralized way we operate our businesses combines the best qualities of smaller companies – an entrepreneurial drive for growth and proximity to customers – with the resources, know-how and investment capital of a well-respected Fortune 500 company. This strategic approach gives us a strong sense of ownership and an agility and accountability seldom seen in large multinational corporations.

Our goal is to form an active partnership where we can bring the full strength of Johnson & Johnson to bear to create a long and valuable relationship.

“Working with Janssen Business Development gives you access, resources, expertise and commitment that you simply can’t find anywhere else.”
Contacts

To learn more about partnership opportunities with Janssen, please contact one of the following Janssen Business Development team members representing the various therapeutic areas in the Pharmaceuticals group.

Patrick E. Verheyen, Global Head, Janssen Business Development

**CARDIOVASCULAR/METABOLISM**
Scott Lundeen, Ph.D.
E: slundeen@its.jnj.com

**EMERGING MARKETS**
Herwig Janssen
E: hjansse4@its.jnj.com

**GLOBAL PUBLIC HEALTH**
Jens Bitsch-Norhave, Ph.D., M.B.A.
E: jbitschn@its.jnj.com

**IMMUNOLOGY**
Simon Blake, Ph.D.
E: sblake5@its.jnj.com

**INFECTIOUS DISEASES/VACCINES**
Philippe Alen, Ph.D., M.B.A.
E: palen@its.jnj.com

**NEUROSCIENCE**
Gregor Macdonald, Ph.D.
E: gmacdon1@its.jnj.com

**ONCOLOGY**
Michael Rycyzyn, Ph.D.
E: mrycyzyn@its.jnj.com

**PULMONARY HYPERTENSION**
Joerg Laeuffer, M.D., M.B.A
E: jlaeuff1@its.JNJ.com